What's Happening?
The Advisory Council on Parkinson's Research, Care and Services (ACPRCS), established under the National Parkinson's Project (NPP), held its third public meeting in Washington, D.C. The meeting focused on public-private partnerships aimed at advancing
diagnostics and treatments for Parkinson’s disease and related disorders (PDRDs), including progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA). Congressional champions, including Representatives Gus Bilirakis (FL) and Paul Tonko (NY), and Senators Shelley Moore Capito (WV) and Chris Murphy (CT), provided opening remarks, emphasizing the importance of measurable goals, continued research, and access to care. Former Representative Jennifer Wexton, living with PSP, delivered recorded remarks via AI-assisted voice recreation, advocating for research investment, improved healthcare professional education, coordinated specialty care, and care partner support. The discussions highlighted the need for clear goals and meaningful involvement from affected communities in public-private partnerships, drawing lessons from programs like Accelerating Medicines Partnership (AMP) ALS.
Why It's Important?
This meeting is crucial for shaping the national strategy to combat Parkinson's disease and related disorders, which affect millions of Americans. The emphasis by congressional leaders on measurable goals and sustained research underscores a commitment to tangible progress in diagnosis and treatment. Public-private partnerships are vital for pooling resources, expertise, and accelerating scientific breakthroughs that might otherwise be delayed. By involving patient organizations and individuals with lived experience, research priorities and study designs can be more effectively tailored to meet the real-world needs of patients and caregivers. Addressing the distinct needs of 'related diseases' like PSP, CBD, and MSA, which have historically been overlooked, ensures a more comprehensive approach to neurological health. Improved diagnostics and accessible treatments can significantly enhance the quality of life for patients, reduce healthcare burdens, and foster innovation in the pharmaceutical and medical technology sectors.
What's Next?
The Advisory Council will hold its next virtual meeting on December 7, 2026, focusing on timely access to high-quality multidisciplinary care that adapts to evolving patient needs. Two public workshops organized by the National Academies are planned for 2027, which will provide additional evidence and perspectives to inform the Council’s recommendations on research, care, services, and support. CurePSP, an advocacy group, will continue its efforts to shape recommendations that translate national priorities into specific actions and measurable progress for all populations served by the NPP. The Council is expected to develop actionable recommendations that address gaps in research infrastructure, resources, and activities tailored to specific PDRDs. Future efforts will also focus on making research participation easier and more responsive to participants' needs, including remote participation options and returning research results to participants, while ensuring diverse representation in studies.
Beyond the Headlines
The use of AI-assisted voice recreation by former Representative Jennifer Wexton highlights the growing role of technology in advocacy and healthcare, offering new ways for individuals with debilitating conditions to share their experiences and influence policy. This also raises broader ethical considerations regarding the use of AI in personal communication and its implications for authenticity and representation. The focus on public-private partnerships reflects a growing trend in medical research, where collaboration between government, academia, industry, and patient groups is seen as essential for tackling complex diseases. This model can accelerate drug discovery and development, but also requires careful navigation of intellectual property rights, funding mechanisms, and equitable access to new therapies. The call for addressing historically overlooked needs of related diseases underscores the importance of inclusive research and healthcare policies that do not leave behind smaller patient populations, ensuring that scientific advancements benefit all those affected by neurological disorders.













